1. Supplemental Appendix 1

Medline (Ovid)

1. exp pregnancy/
2. exp conception/
3. exp gestation/
4. exp childbirth/
5. exp foetus/
6. exp fetus/
7. exp Newborn/
8. pregnan$.tw.
9. gestation$.tw.
11. labo$.tw.
12. fetal$.tw.
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. exp Clinical Trial/
15. exp Cohort Studies/
16. exp Case-control Studies/
17. Prospective Studies/
18. Retrospective Studies/
19. Longitudinal Studies/
20. Follow-up Studies/
21. cohort$.tw
22. (case$ adj5 control$).tw.
23. (longitudinal$ adj5 stud$).tw.
24. (follow$ adj5 stud$).tw.
25. (retrospective$ adj5 stud$).tw.
27. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28. exp Glomerulonephritides, IGA/
29. exp IGA Nephropathy/
30. exp IGA Glomerulonephritis/
31. exp Immunoglobulin A nephropathy/
32. exp Burgers Disease/
33. IGA Glomeruloneph$.tw.
34. IGA Neph$.tw.
35. Immunoglobulin A Glumeruloneph$.tw.
36. Immunoglobulin A Neph$.tw.
38. 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37
39. 13 and 27 and 38

EMBASE

1. pregnancy
2. conception
3. gestation
4. fetus
5. foetus
6. labor
7. newborn
8. new NEAR/5 born
9. childbirth
10. labour*
11. pregnant*
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. clinical trial
14. cohort study
15. case control study
16. prospective study
17. retrospective study
18. longitudinal study
19. follow up study
20. prospective* NEAR/5 stud*
21. retrospective* NEAR/5 stud*
22. follow* NEAR/5 stud*
23. longitudinal* NEAR/5 stud*
24. case* NEAR/5 control*
25. 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26. IgA glomerulonephritis
27. Immunoglobulin A glomeruloneph*
28. IgA nephropathy
29. Immunoglobulin A neph*
30. Bergers disease
31. IgA neph*
32. IgA glomeruloneph*
33. Glomerulonephritides, IGA
34. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33
35. 12 and 25 and 34

**CBM**

检索语句：高级检索（不设年限）

("IgA 肾小球肾炎" OR "Berger 病" OR "IgA 肾病" OR "免疫球蛋白 A 型肾病" OR "肾小球肾炎, IGA") AND ("怀孕" OR "妊娠" OR "分娩" OR "胎儿分娩" OR "妊娠分娩" OR "分娩") AND ("妊娠"[不加权:扩展]) AND "肾小球肾炎, IGA"[不加权:扩展])
Supplement table 1. GRADE assessment of the renal outcomes.

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative riska (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of Participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy on IgAN for IgAN nephropathy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient or population: patients with IgAN nephropathy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Settings:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intervention: pregnancy on IgAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study population</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>425 per 1000</td>
<td>114 per 1000 (76 to 164)</td>
<td>0.59 to 1.37</td>
<td>1198 (9 studies)</td>
<td>@@@@ very low1,2</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>97 per 1000</td>
<td>86 per 1000 (80 to 128)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

C.I. Confidence interval; OR: Odds ratio.

GRADE Working Group grades of evidence:

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

1 Of 9 studies, 2 were retrospective studies and 5 were prospective studies, and 2 were not mentioned whether retrospective studies or prospective studies.

Supplement figure 1.
Begg's funnel plot with pseudo 95% confidence limits
renal outcomes  Begg’s Test  p=0.27

Begg's funnel plot with pseudo 95% confidence limits

eGFR/CCr  Begg’s Test  P=0.86